[{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Innovate UK | Syne Qua Non Limited | IND 2 Results","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Innovate UK | Syne Qua Non Limited | IND 2 Results","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Innovate UK | Syne Qua Non Limited | IND 2 Results"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"American College of Radiology | IND 2 Results | Syne Qua Non Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ American College of Radiology | IND 2 Results | Syne Qua Non Limited","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ American College of Radiology | IND 2 Results | Syne Qua Non Limited"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"F-Fluciclovine","moa":"Amino acid transporters","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"18-F FLT","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gadobenic Acid","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gadobenic Acid","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Radiolabeled Compound","year":"2014","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride Microspheres","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride Microspheres","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride Microspheres","moa":"Homeostasis","graph1":"Neurology","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ PSI CRO","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ PSI CRO"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Blue Earth Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Blue Earth Therapeutics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu-rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F Flotufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Aixial Group","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Aixial Group"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"1","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gadolinium","moa":"Ribonucleoside-diphosphate reductase RR1 | Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"6","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Blue Earth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ Blue Earth Therapeutics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"University College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ University College London"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"7","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Bracco","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Bracco \/ National Institutes of Health"},{"orgOrder":0,"company":"Bracco","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Bracco \/ National Institutes of Health"},{"orgOrder":0,"company":"Bracco","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Bracco \/ National Institutes of Health"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gadoteridol","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Parexel"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Parexel"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3 (18F)","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rubidium-82","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Homeostasis||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Iopamidol","moa":"X-ray contrast agent","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iopamidol","moa":"X-ray contrast agent","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iopamidol","moa":"X-ray contrast agent","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iopamidol","moa":"X-ray contrast agent","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Nicole Hill","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Nicole Hill","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Nicole Hill"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"James Mountz","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ James Mountz","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ James Mountz"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Ali Nabavizadeh","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Blue Earth Diagnostics \/ Ali Nabavizadeh","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Ali Nabavizadeh"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Timothy J. Daskivich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Blue Earth Diagnostics \/ Timothy J. Daskivich","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Timothy J. Daskivich"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Nghi Nguyen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Nghi Nguyen","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Nghi Nguyen"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Bital Savir-Baruch","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"UNII-38R1Q0L1ZE","moa":"Amino acid transporters","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Bital Savir-Baruch","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Bital Savir-Baruch"}]
Find Clinical Drug Pipeline Developments & Deals by Bracco
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
